Pulse Biosciences Valuation Multiples

Pulse Biosciences Overview

About Pulse Biosciences

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

Founded

2014

HQ

Employees

75

Website

pulsebiosciences.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $1M

EBITDA: ($54M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Pulse Biosciences Financials

Pulse Biosciences reported last 12-month revenue of $1M and negative EBITDA of ($54M).

In the same LTM period, Pulse Biosciences generated ($156K) in gross profit, ($54M) in EBITDA losses, and had net loss of ($79M).

Pulse Biosciences P&L

In the most recent fiscal year, Pulse Biosciences reported revenue of $350K and EBITDA of ($50M).

Pulse Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pulse Biosciences Stock Performance

Pulse Biosciences has current market cap of $2B, and enterprise value of $2B.

Pulse Biosciences' stock price is $23.40.

Pulse Biosciences Valuation Multiples

Pulse Biosciences trades at 1182.8x EV/Revenue multiple, and (28.3x) EV/EBITDA.

Pulse Biosciences Financial Valuation Multiples

As of April 20, 2026, Pulse Biosciences has market cap of $2B and EV of $2B.

Equity research analysts estimate Pulse Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pulse Biosciences has a P/E ratio of (20.2x).

Pulse Biosciences Margins & Growth Rates

Pulse Biosciences' revenue in the last 12 month grew by 381%.

Pulse Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Pulse Biosciences' rule of 40 is (859%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pulse Biosciences' rule of X is 480% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Pulse Biosciences Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Pulse Biosciences M&A Activity

Pulse Biosciences acquired XXX companies to date.

Last acquisition by Pulse Biosciences was on XXXXXXXX, XXXXX. Pulse Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pulse Biosciences Investment Activity

Pulse Biosciences invested in XXX companies to date.

Pulse Biosciences made its latest investment on XXXXXXXX, XXXXX. Pulse Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).